RXi Names Lead Drug Candidate Selection, Corporate Partnership as Goals for 2010
April 01, 2010
RXi Names Lead Drug Candidate Selection, Corporate Partnership as Goals for 2010
RXi is "well positioned" to meet its 2010 goals of selecting a product candidate to advance into formal drug development, "refining the [company's] therapeutic focus," and consummating one or more industry partnerships, the company's new CEO said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- RXi Q1 Losses Down, R&D Expenses Up
May 19, 2011 / Gene Silencing News - RXi Q1 Loss Rises on Opko Deal Charge
May 16, 2013 / Gene Silencing News - Alnylam to Release Phase II ATTR Data, Launch Expansion Trial in Coming Months
May 9, 2013 / Gene Silencing News - People in the News: Paul Dorman, Curtis Lockshin
April 25, 2013 / Gene Silencing News - Following Private Placement, RXi Has Funds to Last into 2015
April 4, 2013 / Gene Silencing News